Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.

Status: Recruiting

Protocol number: BO20289

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: An open label 2-arm study to evaluate the impact of adjuvant bevacizumab on Invasive Disease Free Survival in triple negative breast cancer

Brief summary: This 2 arm open-label study will evaluate the efficacy and safety of the addition of Avastin (bevacizumab) to standard adjuvant therapy in patients with triple negative breast cancer. Patients will be randomized to receive either standard chemotherapy (anthracycline +/- taxane or taxane only), or standard chemotherapy given concurrently with 1 year of Avastin (5mg/kg/week dosing equivalent i.v.). The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals. Target sample size is 2530.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Breast Cancer

Intervention type: Drug

Intervention name: bevacizumab [Avastin]

Primary outcome: 1. Invasive disease-free survival Time frame: Event driven

Key secondary outcomes: 1. Overall survival, breast cancer-free interval, disease-free interval, distant disease-free survival. Time frame: Event driven. 2. AEs, and laboratory parameters. Time frame: Throughout study

Inclusion criteria:

  • adult patients, >=18 years of age;
  • operable primary invasive breast cancer;
  • completed definitive loco-regional surgery;
  • primary tumor centrally confirmed as triple negative.

Exclusion criteria:

  • locally advanced breast cancers;
  • previous breast cancer history;
  • clinically significant cardiovascular disease.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: December, 2007

Trial registration date: 09/11/2007

Date last updated: 11/21/2008


Link to trial result

This trial is being conducted at the following locations:

Argentina

  • Buenos Aires
  • Rosario

Australia

  • Adelaide
  • Brisbane
  • Fitzroy
  • Geelong
  • Heidelberg
  • Malvern
  • Melbourne
  • Nambour
  • Parkville
  • Perth
  • Port Macquarie
  • St. Leonards
  • Sydney
  • Waratah
  • Wodonga
  • Wollongong

Austria

  • Bludesch
  • Graz
  • Innsbruck
  • Leoben
  • Salzburg
  • Wels
  • Wien
  • Wiener Neustadt
  • Wolfsberg

Belgium

  • Baudour
  • Bruxelles
  • Hasselt
  • Sint-Niklaas
  • Wilrijk

Bosnia and Herzegovina

  • Sarajevo

Brazil

  • Jaú
  • Porto Alegre
  • Porto Alegre Rs
  • Rio De Janeiro
  • Santo Andre
  • Sao Paulo

Canada

  • Edmonton, AB
  • Surrey, BC
  • Vancouver, BC
  • Winnipeg, MB
  • Moncton, NB
  • St John'S
  • Halifax, NS
  • Kingston, ON
  • Kitchener, ON
  • London, ON
  • Mississauga, ON
  • Oshawa, ON
  • Ottawa, ON
  • Sudbury, ON
  • Toronto, ON
  • Windsor, ON
  • Greenfield Park, QC
  • Montreal, QC
  • Quebec City, QC
  • Saskatoon, SK

China

  • Hong Kong

Costa Rica

  • San José

Czech Republic

  • Brno
  • Novy Jicin
  • Olomouc
  • Pardubice
  • Praha

Finland

  • Tampere
  • Turku

France

  • Angers
  • Bayonne
  • Besancon
  • Bobigny
  • Bordeaux
  • Brest
  • Chaussée Saint Victor
  • Clermont-Ferrand
  • Colmar
  • Grenoble
  • Le Mans
  • Lille
  • Limoges
  • Marseille
  • Montbeliard
  • Montpellier
  • Mougins
  • Nancy
  • Neuilly-Sur-Seine
  • Paris
  • Rouen
  • Saint-Cloud
  • Senlis
  • Strasbourg
  • Toulon
  • Tours

Germany

  • Berlin
  • Bielefeld
  • Chemnitz
  • Coburg
  • Dortmund
  • Dresden
  • Frankfurt Am Main
  • Freiburg
  • Georgsmarienhütte
  • Greifswald
  • Hamburg
  • Heidelberg
  • Herne
  • Kassel
  • Kiel
  • Köln
  • Krefeld
  • Leipzig
  • Lemgo
  • Magdeburg
  • Marburg
  • München
  • Münster
  • Offenbach
  • Recklinghausen
  • Rosenheim
  • Stade
  • Trier
  • Tübingen
  • Ulm
  • Weissenfels
  • Witten

Greece

  • Heraklion
  • Patras
  • Thessaloniki

Israel

  • Haifa
  • Jerusalem
  • Kfar Saba
  • Petah Tikva
  • Ramat Gan
  • Rehovot
  • Tel Aviv

Italy

  • Aviano
  • Bari
  • Bergamo
  • Brescia
  • Brindisi
  • Candiolo
  • Cattolica
  • Cesena
  • Fano
  • Genova
  • Lecce
  • Lido Di Camaiore
  • Livorno
  • Noale
  • Palermo
  • Parma
  • Pavia
  • Potenza
  • Ravenna
  • Ravenna, Emilia Romagna
  • Rimini
  • Roma
  • Rozzano
  • San Giovanni Rotondo
  • Sassari
  • Taormina
  • Treviglio
  • Vecchiazzano

Japan

  • Aichi
  • Fukuoka
  • Kyoto
  • Matsuyama-Shi, Ehime
  • Osaka
  • Saitama
  • Tokyo

Macedonia, The Former Yugoslav Republic of

  • Skopje

Malaysia

  • Kelantan
  • Kuala Lumpur
  • Penang
  • Petaling Jaya, Selangor
  • Selangor

Mexico

  • Leon
  • Monterrey

Netherlands

  • Delftzijl
  • Den Helder
  • Groningen
  • Tilburg

New Zealand

  • Auckland
  • Wellington

Peru

  • Arequipa
  • Lima

Philippines

  • Cebu City
  • Quezon City

Poland

  • Elblag
  • Lodz
  • Lublin
  • Poznan
  • Warszawa

Portugal

  • Coimbra
  • Lisboa

Romania

  • Bucharest
  • Cluj-Napoca

Russian Federation

  • Chelyabinsk
  • Ekaterinburg
  • Ivanovo
  • Kazan
  • Moscow
  • Obninsk
  • Ryazan
  • Samara
  • St Petersburg
  • Ufa

Singapore

  • Singapore

South Africa

  • Bloemfontein
  • Durban
  • Johannesburg
  • Pietermaritzburg
  • Pretoria

Spain

  • Barcelona
  • Burgos
  • Gijon
  • Girona
  • La Laguna
  • Madrid
  • Malaga
  • Mataro
  • Navarra
  • Palma de Mallorca
  • Pontevedra
  • Terrassa
  • Valencia
  • Zaragoza

Sweden

  • Gaevle
  • Lund
  • Malmoe
  • Umea
  • Uppsala

Switzerland

  • Aarau
  • Basel
  • Bern
  • Chur
  • Thun
  • Winterthur
  • Zuerich

Taiwan

  • Changhua
  • Kaohsiung
  • Tainan
  • Taipei
  • Taoyuan

Thailand

  • Bangkok
  • Chiang Mai
  • Songkhla

United Kingdom

  • Belfast
  • Birmingham
  • Bournemouth
  • Brighton
  • Bristol
  • Cambridge
  • Cardiff
  • Chelsmford
  • Colchester
  • Dundee
  • Edinburgh
  • Epping
  • Exeter
  • Glasgow
  • Guildford
  • Huddersfield
  • Leeds
  • London
  • Manchester
  • Merseyside
  • Newcastle upon Tyne
  • Northwood
  • Peterborough
  • Sheffield
  • Stoke-on-Trent
  • Truro
  • Wolverhampton

United States

  • Huntsville, AL
  • Mobile, AL
  • Fayetteville, AR
  • Bakersfield, CA
  • Fountain Valley, CA
  • Greenbrae, CA
  • Los Angeles, CA
  • Pleasant Hill, CA
  • Fairfield, CT
  • Stamford, CT
  • Washington, DC
  • Gainesville, FL
  • Orlando, FL
  • Tamarac, FL
  • Atlanta, GA
  • Augusta, GA
  • Lawrenceville, GA
  • Park Ridge, IL
  • Iowa City, IA
  • Waterloo, IA
  • Baltimore, MD
  • Rockville, MD
  • Kalamazoo, MI
  • Southfield, MI
  • Woodhaven, MI
  • Kansas City, MO
  • St Louis, MO
  • Long Branch, NJ
  • Bronx, NY
  • Hickory , NC
  • Cincinnati, OH
  • Columbus, OH
  • Middletown, OH
  • Columbia, SC
  • Chatanooga, TN
  • Germantown, TN
  • Nashville, TN
  • Austin, TX
  • Dallas, TX
  • Rutland, VT
  • Abingdon, VA
  • Richmond, VA

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply